Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fragment-Based Library Generation for the Discovery of a Peptidomimetic p53-Mdm4 Inhibitor
André Boltjes, Yijun Huang, Rob van de Velde, et al.
ACS Combinatorial Science (2014) Vol. 16, Iss. 8, pp. 393-396
Open Access | Times Cited: 20

Showing 20 citing articles:

State-of-the-art strategies for targeting protein–protein interactions by small-molecule inhibitors
Chunquan Sheng, Guoqiang Dong, Zhenyuan Miao, et al.
Chemical Society Reviews (2015) Vol. 44, Iss. 22, pp. 8238-8259
Closed Access | Times Cited: 148
Discovery of Novel Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2–p53 Interaction
Andreas Gollner, Dorothea Rudolph, Heribert Arnhof, et al.
Journal of Medicinal Chemistry (2016) Vol. 59, Iss. 22, pp. 10147-10162
Closed Access | Times Cited: 109
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
Yuan Fang, Guochao Liao, Bin Yu
Acta Pharmaceutica Sinica B (2020) Vol. 10, Iss. 7, pp. 1253-1278
Open Access | Times Cited: 80
MDMX in Cancer: A Partner of p53 and a p53-Independent Effector
Lin Wu, Yuxiang Yan, Qingling Huang, et al.
Biologics (2024) Vol. Volume 18, pp. 61-78
Open Access | Times Cited: 7
Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis
James A. McCubrey, Kvin Lertpiriyapong, Timothy L. Fitzgerald, et al.
Advances in Biological Regulation (2016) Vol. 63, pp. 32-48
Closed Access | Times Cited: 52
Synthesis and screening of small-molecule α-helix mimetic libraries targeting protein–protein interactions
Heejo Moon, Hyun‐Suk Lim
Current Opinion in Chemical Biology (2014) Vol. 24, pp. 38-47
Closed Access | Times Cited: 46
Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges
Dehua Yu, Zhiyuan Xu, Shaowei Mo, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 39
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets
Elke Tatjana Aristizabal Prada, Christoph J. Auernhammer
Endocrine Connections (2017) Vol. 7, Iss. 1, pp. R1-R25
Open Access | Times Cited: 30
MCR synthesis of a tetracyclic tetrazole scaffold
Pravin Patil, Kareem Khoury, Eberhardt Herdtweck, et al.
Bioorganic & Medicinal Chemistry (2014) Vol. 23, Iss. 11, pp. 2699-2715
Open Access | Times Cited: 29
Active fragments-guided drug discovery and design of selective tropane alkaloids using ultra-high performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometry coupled with virtual calculation and biological evaluation
Mengge Zhou, Xiaoyao Ma, Jixue Sun, et al.
Analytical and Bioanalytical Chemistry (2016) Vol. 409, Iss. 4, pp. 1145-1157
Closed Access | Times Cited: 24
MDM4 alternative splicing and implication in MDM4 targeted cancer therapies.
Jin Wu, Guanting Lu, Xinjiang Wang
PubMed (2021) Vol. 11, Iss. 12, pp. 5864-5880
Closed Access | Times Cited: 19
Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment
Cristina Camps-Fajol, Debora Cavero, Jordi Minguillón, et al.
Pharmacological Research (2024) Vol. 211, pp. 107544-107544
Open Access | Times Cited: 1
Drug Design Methods to Regulate Protein–Protein Interactions
Krishna Mohan Poluri, Khushboo Gulati, Deepak Kumar Tripathi, et al.
(2023), pp. 265-341
Closed Access | Times Cited: 2
Fragment-Based Drug Discovery for Developing Inhibitors of Protein-Protein Interactions
Bing Xiong, Qi Wang, Jingkang Shen
Springer eBooks (2018), pp. 135-176
Closed Access | Times Cited: 4
Protein–Protein Interaction Inhibitors in Cancer
IR Hardcastle
Elsevier eBooks (2016), pp. 154-201
Closed Access | Times Cited: 3
Late-stage diversification of peptidomimetics and oligopeptides via gold-catalyzed post-Ugi cyclization
Liangliang Song, Chao Liu, Guilong Tian, et al.
Molecular Catalysis (2022) Vol. 522, pp. 112240-112240
Open Access | Times Cited: 3
High-Throughput Screening in the Discovery of Small-Molecule Inhibitors of Protein-Protein Interactions
Chunlin Zhuang, Chunquan Sheng
Springer eBooks (2018), pp. 29-51
Closed Access | Times Cited: 2
Peptide and peptidomimetic-based vaccines
Abhishek Singh, Mukesh Thakur
Elsevier eBooks (2022), pp. 457-471
Closed Access | Times Cited: 1

Abdul Jabbar Shah, B Barathi, Anroop B. Nair, et al.
International Journal of Pharmaceutical Sciences and Research (2017) Vol. 8, Iss. 12
Open Access
Page 1

Scroll to top